Evolent Health, Inc. (EVH) Company Overview

Evolent Health, Inc. is a New York Stock Exchange-listed healthcare company that helps health plans and other risk-bearing organizations manage costly, clinically complex specialties. Its operating focus is narrower than a general healthcare-services platform: Evolent concentrates on oncology, cardiology, musculoskeletal care, advanced imaging, diagnostics and genetics, and related specialty-care workflows. The company reports as one operating segment because management evaluates the platform on a consolidated basis rather than as independent divisions.

Who pays Evolent, and who uses the platform?

The paying customer is generally a health plan, employer-sponsored risk entity, government-sponsored managed-care organization, or another payer that wants better specialty outcomes and lower medical expense. Providers and clinical teams are the daily users. Evolent combines provider networks, evidence-based clinical pathways, utilization-management tools, care navigation, analytics, and claims-risk arrangements. Its official solutions portfolio shows how the company packages these capabilities across specialty conditions rather than selling a single software product.

This distinction matters for analysis. Evolent is partly a technology-enabled services company and partly a medical-risk manager. A fee-only contract resembles recurring healthcare administration revenue; a capitation contract can produce much more revenue but also exposes Evolent to claims volatility. The same clinical platform therefore supports two very different financial profiles.

Evolent’s revenue model is organized around four commercial categories. The most important difference is whether Evolent receives a fixed administrative fee or accepts responsibility for medical claims. Pricing is often quoted on a per-member-per-month basis, so member volume, population type, benefit design, geographic mix, and the number of specialties covered all affect revenue.

What are the four revenue engines?

Which category drives the current model?

The revenue mix explains why top-line growth can be misleading. A new Performance Suite contract may add hundreds of millions of dollars of revenue, yet much of that amount represents claims that Evolent must pay. Investors therefore need to study medical-expense performance and adjusted EBITDA alongside revenue. Fee-based growth is usually less capital intensive; risk-bearing growth creates more upside if clinical interventions lower claims, but more downside if pricing or reserve assumptions are wrong.

The quarter ended March 31, 2026 showed a business growing again after the divestiture of Evolent Care Partners, but with pressure in the risk-bearing book. Revenue increased because a new Performance Suite contract went live; adjusted profitability fell because that contract was still in an early maturation phase and carried a high medical expense ratio.

Why did revenue growth not translate into margin growth?

Management attributed the pressure principally to the maturation profile of the new Performance Suite contract. Claims incurred were $301.8M in Q1 2026, while Performance Suite revenue was $323.3M. That narrow spread is the central operating issue. Evolent must improve care pathways, network performance, authorization accuracy, and reserve estimates before the contract produces a normal contribution margin.

What is management guiding for in 2026?

Evolent reiterated full-year 2026 guidance for revenue of $2.4B to $2.6B and adjusted EBITDA of $110M to $140M. It also expects $25M to $30M of capitalized software-development cash spending. The company’s Q1 2026 earnings release also highlighted an advanced-imaging contract covering roughly 4.5M lives and a national payer expansion expected to contribute more than $200M of annual revenue after planned third-quarter launches, subject to approvals.

Evolent began as a broad value-based-care enablement company and gradually became a focused specialty manager. The strategic logic was that complex specialties offer more concentrated clinical variation, higher medical cost, and clearer opportunities to combine clinical pathways with payer economics.

From value-based infrastructure to specialty risk

1. 2011
   Evolent was founded by management, UPMC, and The Advisory Board Company to help providers operate in value-based payment models. That provider heritage still shapes its clinical-network approach.
2. 2015
   The company completed its initial public offering, selling 13.2M shares at $17 per share. Public capital funded expansion, but also exposed investors to a long transition from growth to durable cash generation.
3. 2018
   The acquisition of New Century Health established the core oncology and cardiology platform that now anchors Performance Suite economics.
4. 2021
   Vital Decisions expanded advanced-care planning, adding a case-based service and deeper engagement in serious illness.
5. 2022
   Integrated Specialty Pharmacy Group broadened surgical and musculoskeletal management, increasing the number of specialty cost pools Evolent could address.
6. 2023
   The NIA acquisition added advanced imaging, musculoskeletal, and genetic-testing capabilities. Evolent then unified its commercial identity around value-based specialty care through an official specialty-care rebrand.
7. 2024
   Machinify added AI-enabled chart review and utilization-management workflow capabilities, supporting faster approvals and clinical decision preparation.
8. 2025
   Evolent sold Evolent Care Partners to Privia Medical Group. The transaction narrowed the company to specialty care and supplied cash for debt reduction, but removed a meaningful revenue stream.

The 2025 divestiture is especially important. Evolent received $91.3M of cash proceeds after working-capital adjustments and repaid $82.8M of principal on its first-lien term loan. The announced ECP sale clarified strategy and helped deleverage, yet it did not eliminate the company’s broader debt burden. Today’s investment case is therefore simpler operationally but still financially leveraged.

Evolent’s advantage is not a consumer brand or a patented drug. It is an operating system for specialty-care management that combines clinical evidence, payer contracts, provider relationships, workflow technology, and the willingness to take medical risk. These resources are difficult to assemble together, although none is impossible for a large payer or integrated healthcare-services company to replicate.

Where are the strongest moat elements?

The oncology offering illustrates this combination. Evolent reports that its pathways cover 99% of cancer diseases, that typical new partners have seen more than a 30% increase in pathway adherence, and that about 50% of medical-oncology regimens submitted through its portal can be auto-authorized. These are company-reported solution metrics rather than audited segment KPIs, but they show the intended mechanism: reduce administrative friction while steering treatment toward evidence-based choices. The official oncology page also reports 82% provider satisfaction.

Which competitive forces can erode that advantage?

This is the most healthcare-specific part of the analysis. In Performance Suite, Evolent receives capitated revenue and records claims expense for covered services. Profitability depends on the spread between those two amounts after clinical and administrative costs. A contract can therefore produce strong reported revenue while destroying value if pricing is insufficient, claims rise faster than expected, or reserves are understated.

Which operating KPIs explain unit economics?

How does a Performance Suite contract convert to profit?

Medical expense ratio is the first KPI to examine, but not the only one. Researchers should also monitor claims-reserve development, covered lives, PMPM pricing, the age of newly launched contracts, and fee-based service growth. The detailed Q1 2026 Form 10-Q shows why these variables belong together: a higher PMPM can coexist with lower EBITDA when the associated claims profile is unfavorable.

Evolent has adequate liquidity for operations, but its balance sheet leaves little room for complacency. The company is not yet a consistently strong free-cash-flow compounder. It carries substantial debt, high interest expense, large acquired intangible balances, and a recent impairment history. At the same time, the ECP sale and debt repayments show management is actively simplifying the capital structure.

What changed between FY2025 and Q1 2026?

Does reported EBITDA become cash?

The proxy shows that FY2025 adjusted EBITDA of $151.2M did not translate into comparable discretionary cash. Working capital, interest, restructuring, claims timing, and capitalized software absorb cash. A robust valuation should therefore forecast cash directly rather than apply a simple EBITDA multiple. The company’s FY2025 results release is useful for reconciling reported and adjusted profitability.

Evolent has dispersed institutional ownership rather than founder voting control. As of April 9, 2026, 114.0M Class A shares were outstanding. The proxy table lists several large investment managers, while the chief executive and co-founder owns less than 1%. Economic ownership and voting influence are therefore broadly aligned, and board oversight matters more than a dual-class structure.

What governance signals should researchers notice?

The board was fully declassified, the chair was independent, and all standing committees were composed of independent directors. The company also reported no poison pill and no supermajority voting provisions. Executive incentives are financially weighted: 85% of the short-term incentive framework is tied to company-wide financial objectives and 15% to strategic, team, and individual goals. The structure encourages measurable operating outcomes, although investors still need to examine whether adjusted metrics adequately reflect cash and balance-sheet costs.

Evolent’s opportunity is large because specialty care is expensive, clinically complex, and operationally fragmented. Its risk is equally direct: the company must make credible medical-cost commitments before all claims are known. Growth therefore improves the story only when contracts mature into dependable margins and cash flow.

Where could growth come from?

Which risks are most material?

AI deserves a nuanced reading. Evolent states that it does not use AI to deny care: clinical professionals make denial decisions, while AI may support chart review or automate approvals. That policy can help with trust and regulatory positioning, but it does not eliminate model-error, privacy, cyber, or implementation risk. The broader company strategy and operating philosophy emphasize better health outcomes, which must be demonstrated through measurable partner economics rather than mission language alone.

Evolent is important because it sits at the intersection of two powerful healthcare trends: payers need tighter control of specialty medical cost, and providers need less administrative friction. The company has built an unusually broad specialty platform through acquisitions, payer partnerships, provider networks, clinical pathways, and technology. That platform creates real switching costs and growth options, but the financial model remains sensitive to medical claims, contract timing, customer concentration, and leverage.

Which variables matter most in a DCF?

• Next-quarter proof point: whether the 93.3% Q1 2026 Performance Suite MER begins to normalize.
• Launch execution: timing and early economics of the 4.5M-life imaging contract and the payer expansion expected to exceed $200M of annual revenue.
• Margin quality: adjusted EBITDA growth versus reported operating profit and operating cash flow.
• Balance-sheet progress: cash, debt, interest expense, and the treatment of convertible notes.
• Customer stability: retention and cross-sell among the four partners that produced 68.5% of FY2025 revenue.
• Governance discipline: whether capital allocation prioritizes durable cash generation and deleveraging.